IHS Chemical Week

Pharma/fine chemicals roundup—7 April 2015

April 7, 2015 | By DEEPTI RAMESH

Aptuit expands API capacity in Italy and UK Aptuit (Greenwich, CT) says that it has increased its capacity for active pharmaceutical ingredient (API) manufacture in Italy and the United Kingdom due to increased demand for APIs, and for integrated and comprehensive candidate-to- investigational new drug (IND) development solution. “Customer demand for our integrated, fully inclusive candidate-to-IND...

Pharma/fine chemicals roundup—31 March 2015

March 31, 2015 | By DEEPTI RAMESH

Sun Pharma completes acquisition of Ranbaxy Sun Pharmaceutical Industries (Mumbai) says that it has completed the previously announced acquisition of Ranbaxy Laboratories (Gurgaon, India). Sun Pharma announced in April 2014 that it would acquire Ranbaxy in an all-stock transaction valued at about $3.2 billion. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. With the...

FDA to use metrics initiative to improve drug quality throughout supply chain

March 26, 2015 | By LAWRENCE SLOAN

Combating drug quality and supply shortages are ongoing concerns for stakeholders throughout the pharmaceutical supply chain, including members of SOCMA’s Bulk Pharmaceuticals Task Force (BPTF). As a means to address these concerns, the U.S. Food and Drug Administration (FDA) is working with the pharmaceutical supply chain on a new Quality Metrics Initiative (QMI). This new initiative, which has been...

Pharma/fine chemicals roundup—24 March 2015

March 24, 2015 | By DEEPTI RAMESH

Weifa to spin off API business Weifa (Oslo), Norway's leading fully-integrated pharmaceutical company and a major supplier of active pharmaceutical ingredients (APIs), says that its board plans to separate the company’s consumer health-care and API operations through a transfer of its API business and tablet production to Vistin Pharma, a newly established subsidiary of Weifa that will be listed on...

Moving forward on white biotech


Industrial biotechnology, also known as white biotech, presents some truly game changing opportunities for the manufacturing sector. In particular, it is serving as a source of raw materials and intermediates that may be cheaper, more sustainable, and offer advantages in terms of performance that were never imaginable with materials produced by more conventional ‘straight chemical’...

Pharma/fine chemicals roundup—17 March 2015

March 17, 2015 | By DEEPTI RAMESH

FDA issues warning letter to Novacyl’s API plant in Thailand FDA issued a warning letter on 27 February to the active pharmaceutical ingredient (API) manufacturing facility of Novacyl Thailand —located in the Bangpoo Industrial Estate in Samut Prakan province—for violations of cGMP. Novacyl Thailand is a subsidiary of Novacyl (Lyon, France). The warning letter was published on the FDA Web...

Pharma/fine chemicals roundup—10 March 2015

March 10, 2015 | By DEEPTI RAMESH

Patheon to acquire API manufacturer IRIX Pharmaceuticals Patheon (Durham, NC), a provider of drug development and delivery solutions to the pharmaceutical and biopharma sectors, says that it has reached a definitive agreement to acquire IRIX Pharmaceuticals (Florence, SC), a company that specializes in difficult-to-manufacture active pharmaceutical ingredients (APIs) for drugs from early and late...

Pharma/fine chemicals roundup—3 March 2015

March 3, 2015 | By DEEPTI RAMESH

Pharmaceutical market in Japan to reach $80 billion by 2020 Japan’s pharmaceutical market value is set to grow at a compound annual growth rate (CAGR) of 1.3% from $72.8 billion in 2013 to reach $79.8 billion by 2020, driven by new product launches and the health care burden of the country’s aging population, according to research and consulting firm GlobalData (London). The market was valued...

Pharma/fine chemicals roundup—24 February 2015

February 24, 2015 | By DEEPTI RAMESH

Granules OmniChem JV opens API plant in India Granules India (Hyderabad), a producer of active pharmaceutical ingredients (APIs), intermediates, and formulations, says that its Granules OmniChem joint venture has opened its previously announced new manufacturing facility for APIs and pharma intermediates at Visakhapatnam, India. Granules India formed Granules OmniChem — a 50-50 jv with pharmaceutical...

Pharma/fine chemicals roundup—17 February 2015

February 17, 2015 | By DEEPTI RAMESH

AMRI to close API plant in UK Albany Molecular Research Inc. (AMRI; Albany, NY) announced on 12 February that it plans to close its facility at Holywell, UK, which provides chemical development services and small- and large-scale manufacturing services of active pharmaceutical ingredients (APIs). Nearly 64 employees will be affected by the proposed closure of the plant, the company says. “The...


Welcome to Chem Ideas, the place for opinions and perspective on the key issues affecting the global chemicals industry. This zone features articles by Chemweek’s regular editors as well as a team of established experts with insights across the chemicals industry. If you would like to contribute a blog or opinion piece contact rob.westervelt@ihs.com.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa